Tonix Pharmaceuticals   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: New York NY United States (2007)

Organization Overview

First Clinical Trial
2011
NCT01490788
First Marketed Drug
2016
sumatriptan (zecuity)
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

TONIX MEDS | Tonix Pharmaceuticals | Tonix Pharmaceuticals, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Collagen Diseases (Phase 3)

Disease (Phase 2)

Fibromyalgia (Phase 3)

Headache (Phase 2)

Muscular Diseases (Phase 3)

Musculoskeletal Diseases (Phase 3)

Myofascial Pain Syndromes (Phase 3)

Nervous System Diseases (Phase 3)

Neuromuscular Diseases (Phase 3)

Rheumatic Diseases (Phase 3)

Stress Disorders, Post-Traumatic (Phase 3)

Tension-Type Headache (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 30
  • # of Trial APIs: 11